Advaccine Clinical Research are developing a vaccine called BARS13 for the active
immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old)
for the seasonal prevention of Respiratory Syncytial Virus (RSV) infection. A total of 120
volunteers aged 60 - 80 years (inclusive) will be enrolled in this study, and will be divided
into 3 groups (or 'cohorts') of 40 people per cohort. The aim of the study is to evaluate the
safety and tolerability of BARS13 in this age group.